Management of antiviral resistance in patients with chronic hepatitis B

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 679-693

  Locarnini, Stephen ^a   Hatzakis, Angelas ^b   Heathcote, Jenny ^c   Keeffe, Emmet B ^d   Liang, T Jake ^e   Mutimer, David ^f   Pawlotsky, Jean Michel ^g   Zoulim, Fabien ^h  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g HENRI MONDOR HOSPITAL   (France)

^h HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; DNA POLYMERASE; EMTRICITABINE; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ALGORITHM; ASSAY; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS HEPATITIS; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; TREATMENT FAILURE; VIRAL LOAD;

EID: 7244262077     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Lee W. Hepatitis B virus infection. New England Journal of Medicine 1997; 337:1733-1745.
2. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38:S18-S23.
3. Torresi J & Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections, Gastroenterology 2000; 118:583-5103.
4. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sannchez-Tapias J, Christensen E, Giustina G & Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. Journal of Hepatology 1994; 21:656-666.
5. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, Cote J & Richer G. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106:1000-1005.
6. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS & Chen CJ for the Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine 2002; 347:168-174.
7. Mommeja-Marin H, Mondou E, Blum R & Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37:1309-1319.
8. Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, Tobias H & Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clinical Gastroenterology & Hepatology 2004; 2:87-106.
9. Lok ASF & McMahon BJ. Chronic hepatitis B. Hepatology 2004; 39:857-861.
10. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. 14-16 September 2002, Geneva, Switzerland. Journal of Hepatology 2003; 39:51-235.
11. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32:866-867.
12. Nowak M, Bonhoeffer S, Hill A, Boehme R, Thomas H & McDade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences, USA 1996; 93:4398-4402.
13. Girones R & Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595-597.
14. Richman DD. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Research 1996; 29:31-33.
15. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG & Arnold E. Molecular modelling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 2001; 75:4771-779.
16. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DLJ, Brown N for the Lamivudine Clinical Investigation Group & Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:670-1677.
17. Lai CL, Leung NWY, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D & Brown N. Results of a one-year international phase UB comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B. Hepatology 2003; 38:262A Abstract 219.
18. Tenny DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S & Collono RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrobial Agents & Chemotherapy 2004; 48:3498-3507.
19. Delaney WE 4th, Locarnini S & Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chemistry & Chemotherapy 2001; 12:1-35.
20. Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD & Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. Journal of Virology 2003; 77:11833-11841.
21. Angus P, Vaughan R, Xiong S, Yang H, Delaney WE, Gibbs C, Brosgart C, Colledge D, Edwards, R, Ayres A, Bartholomeusz A & Locarnini S. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
22. Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL & Xiong S for the 437 and 438 Study Teams. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96-103.
23. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trepo C & Zoulim F. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. Journal of Hepatology 2003; 39:1085-1089.
24. Qi X, Snow A, Thibault V, Zhu Y, Curtis M, Hadziyannis SJ, Brosgart CL, Currie G, Arterburn S, Gibbs CS, Miller MD & Xiong S. Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy. Journal of Hepatology 2004; 40(Suppl. 1):20-21. Abstract 57.
25. Doo E & Liang JT. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120:1000-1008.
26. Naeger LK & Miller MD. Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out? Current Opinion in Investigational Drugs 2001; 2:335-339.
27. Bartholomeusz T, Tehan BG & Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antiviral Therapy 2004; 9:149-160.
28. Dent B, Chin R, Trautwein C, Bock T, Manns M, Cleary D, Furman P & Locarnini S. Antiviral cross-resistance profiles of two novel antiviral agents, DAPD and L-FMAU, against nucleoside-analogue resistant HBV. Hepatology 2000; 32(4 pt 2):457A. Abstract 1191.
29. Xiong S, Yang H, Westland CE, Delaney WE 4th, Colledge D, Bartolomeusz A, Thibault V, Benhamou Y, Angus P, Wulfsohn M, Gibbs CS, Fry J, Brosgart CL & Locarnini S. Resistance surveillance of HBeAg-negative chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology 2003; 38(Suppl. 2):182. Abstract 4543.
30. Si Ahmed SN, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C & Zoulim F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32:1078-1088.
31. Melegari M, Scaglioni P & Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
32. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ & Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 2001; 107:449-455.
33. Chen R, Edwards R, Shaw T, Colledge D, Delaney IV WE, Isom H, Bowden S, Desmond P & Locarnini S. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35.
34. Zhang YY & Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. Journal of Virology 1999; 73:3616-3622.
35. Zhang YY & Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. Journal of Virology 2000; 75:5257-5265.
36. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD & Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrobial Agents & Chemotherapy 1999; 43:1947-1954.
37. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L & Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581-1586.
38. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, Dienstag J, Adams P, Dickson R, Anschuetz G, Bell S, Condreay L, Brown N & the Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-432.
39. Saldanha J, Gerlich W, Lelie N, Dawson P, Heerman K, Heath A & the WHO Collaborative Study. An international collaborative study to establish a world health organization standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001; 80:63-71.
40. Lewin S, Ribeiro RM, Walter T, Lau GKK, Bowden DS, Locarnini S & Perelson AS. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34:1012-1120.
41. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003; 348:808-816.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Broossgart CL. Adefovir dipivoxil for the treatment of HBeAg-negative chronic hepatitis B. New England Journal of Medicine 2003; 348:800-807.
43. Hadziyannis SJ & Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-624.
44. Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K & Sablon E. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DNA DR assay. Journal of Clinical Microbiology 2002; 40:3729-3734.
45. Seignères B, Pichoud C, Martin P, Furman P, Trépo C & Zoulim F. Inhibitory activity of dioxalane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002; 36:710-722.
46. Pichoud C, Seignères B, Wang Z, Trépo C & Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29:230-237.
47. Yang H, Westland C, Xiong S & Delaney WE 4th. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Research 2004; 61:27-36.
48. Durantel D, Durantel S, Pichoud C, Trépo C & Zoulim F. A novel phenotypic assay for monitoring HBV drug resistance during antiviral treatment. Journal of Hepatology 2004 (in press).
49. Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, Brown N, Woessner M, Boehme R & Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clinical Infectious Disease 2003; 36:687-696.
50. Liaw YF, Chien RN, Yeh CT, Tsai SL & Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567-572.
51. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A & Papaioannou CP. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
52. Lok ASF, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD & Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
53. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu Pc, Dent JC, Edmundson S, Condreay LD & Chien RN on behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances e antigen seroconversion rates; results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
54. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF & Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-117.
55. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V & Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219-226.
56. Yuen MF, Kato T, Mizokami M, Chan AOO, Yuen JCH, Yuan HJ, Wong DKH, Sum SM, Ng IOL, Fan ST & Lai CL. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. Journal of Hepatology 2003; 39:850-855.
57. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM & Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714-717.
58. Chan HLY, Chui AKK, Lau WY, Chan FKL, Hui AY, Rao N, Wong J, Lai ECH & Sung JJY. Impact of lamivudine resistant mutants in hepatitis B virus related liver diseases after liver transplantation. Hepatology 2003; 38:Abstract 779.
59. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, Boxall L, O'Donnell K, Shaw J, Hübscher S & Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107-113.
60. Lampertico P, Vigano M, Lavarone M, Lunghi G, Romeo R, Colucci G, Morabito A, Del Ninno E & Colombo M. The long-term outcome of HBeAg-negative patients with cirrhosis treated with lamivudine monotherapy: a 5-year prospective cohort study. Journal of Hepatology 2004; 40(Suppl. 1):16-17. Abstract 44.
61. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, Fyfe J, Sozzi T & Jackson DC. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
62. Thibault V, Aubron-Olivier C, Agut H & Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133.
63. Locarnini SA. Hepatitis B virus surface and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 27:294-297.
64. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S & Sasadeusz J. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV coinfected individuals. AIDS 2003; 27:1649-1657.
65. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER & Brown NA. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-22.
66. Conjeevaram HC & Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34:204-206.
67. Besisik F, Karaca Ç, Akyüz F, Horosanli S, Önel D, Badur S, Sever MS, Danalioglu S, Çakaloglu Y & Ökten A. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. Journal of Hepatology 2003; 38:506-510.
68. Bowden S, Bartholomeusz A & Locarnini S. Lamivudine resistant occult HBV: implications for public health. Journal of Hepatology 2003; 38:526-528.
69. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H & Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791.
70. Ide T, Kumashiro R, Koga Y, Tanaka E, Hino T, Hisamochi A, Murashima S, Ogata K, Tanaka K, Kuwahara R & Sata M. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. American Journal of Gastroenterology 2003; 98:2048-2051.
71. Colgrove R & Japour A. A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Research 1999; 41:45-56.
72. Sung JJY, Lai JY, Zeuzem S, Chow WC, Heathcote E, Perrillo R, Brosgart C, Woessner M, Scott SA & Campbell FM. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): week 52 analysis. Journal of Hepatology 2003; 38:25-26. Abstract 69.
73. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y & Kumada H. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. Journal of Gastroenterology 2002; 37:922-927.
74. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP & Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122:264-273.
75. Wong VWS, Chan HLY, Wong ML, Tam JSL & Leung NWY. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Alimentary Pharmacology & Therapeutics 2004; 19:323-329.
76. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K & Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 1998; 27:1711-1716.
77. Lim SG, Wai CT, Rajnakova A, Kajiji T & Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51:597-599.
78. Liaw YF, Chien R & Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antiviral Therapy 2004; 9:257-262.
79. Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, Hung CH, Chen WJ & Changchien CS. Comparison of clinical outcome between patients with and without continuing lamivudine therapy after biochemical breakthrough of YMDD mutants. Journal of Hepatology 2004; 41:454-461.
80. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee W, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart C & Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90.
81. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray DF, Sullivan M, Kleber K, Ebrahimi R, Xiong S & Brosgart C. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101.
82. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J & Brosgart CL; Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419-1427.
83. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P & Pillay D. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49:860-863.
84. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S & Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49:436-440.
85. Benhamou Y, Vig P, Valatin M, Guyon P, Katlama C, Lu B, Currie G & Brosgart C. Long-term treatment with ADV for three years in patients with lamivudine-resistant HBV and HIV coinfection results in significant and sustained clinical improvement. Hepatology 2003; 38(Suppl. 1):714A. Abstract 1158.
86. Delaney W 4th, Westland CE, Yang HL, Lin KY, Das K, Arnold E, Jain AK, Miller MD, Gibbs CS & Xiong X. Cross-resistance analysis of lamivudine, adefovir, and entecavir using a cell culture model of HBV replication. Antiviral Research 2001; 50:A81. Abstract 145.
87. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S & Colonno RJ. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents & Chemotherapy 2002; 46:2525-2532.
88. Ying C, De Clercq E, Nicholson W, Furman P & Neyts J. Inhibition of the replication of the DNA polymerase mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 2000; 7:161-165.
89. Benhamou Y, Piketty C, Katlama C, Rozenbaum W, Neau D, Lafeuillade A, Rev D, Yazdanpanah Y & Trimoulet P, Fleury H. Efficacy of tenofovir disoproxil fumarate (TDF) for hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infected patients. Hepatology 2003; 38(Suppl. 1):712A. Abstract 1115.
90. Yang H, Qi X, Das K, Arnold WE, Westland CE, Delaney WE 4th, Brosgart CL, Gibbs CS, Miller MD & Xiong S. In vitro characterization and molecular modelling analysis of a novel adefovir resistance mutation RTN236T in the HBV polymerase. Journal of Hepatology 2004; 40(Suppl. 1):114. Abstract 383.